Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens

In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed wi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology- oncology and stem cell research 2014, Vol.8 (2), p.21-26
Main Authors: Ahmadzadeh, Ahmad, Yekaninejad, Mir Saeed, Jalili, Mohamad H, Bahadoram, Mohammad, Efazat, Mehdi, Seghatoleslami, Mohammad, Yazdi, Fatemeh, Mahdipour, Mozhdeh, Valizadeh, Armita, Saki, Najmaldin
Format: Article
Language:English
Subjects:
Chemotherapy
Hodgkin
Original
Second malignancy
Survival
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 26
container_issue 2
container_start_page 21
container_title International journal of hematology- oncology and stem cell research
container_volume 8
creator Ahmadzadeh, Ahmad
Yekaninejad, Mir Saeed
Jalili, Mohamad H
Bahadoram, Mohammad
Efazat, Mehdi
Seghatoleslami, Mohammad
Yazdi, Fatemeh
Mahdipour, Mozhdeh
Valizadeh, Armita
Saki, Najmaldin
description In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with Hodgkin's lymphoma without any age restriction. After gathering all their data, we calculated their survival rate and the chance for a relapse and the secondary malignancies. 389 patients were included in the study with an average age of 27.5 years old and they had received only chemotherapy regimens. 87.9% of them had been treated by ABVD and 12.1 % by Stanford V regimen. 23.1% of them experienced a relapse and 13.1% of all patients, passed away during the study. Secondary malignancies were observed in 11 cases. An overall mean survival time of 295.31 months was resulted. The secondary malignancies after treating Hodgkin's lymphoma patients are different between chemotherapy regimens and chemotherapy – radiotherapy.
format article
fullrecord <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_68f6e9b8cf7d4cbaa33f31a5953fd24f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_68f6e9b8cf7d4cbaa33f31a5953fd24f</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_4003439</sourcerecordid><originalsourceid>FETCH-LOGICAL-d247t-b4ea81ea1af5651f7b0694d050908dc58af5cd3b67eb314322a3c4a9af3f42593</originalsourceid><addsrcrecordid>eNpVkE1Lw0AQhoMoVmr_w948BTbZzcdeBCnVFipKrecw2Z1NVpNN2KSVHv3nLqaXnmZ4hnmYd66Cu5jSPIxjml2fe0apmAWLYTAl5TzjVKT0NpjFPKeUsuQu-F0doTnAaGxFxhrJx8EdjUdkByMSsGqiKDurwJ3IKzSmsmClwYGAHtGRvcNpf92p6tvYh4FsT21fdy2Qdz9BOw7kx4w1WdbYdt7noD-RHVamRTvcBzcamgEX5zoPPp9X--U63L69bJZP21DFPBvDkiPkEUIEOkmTSGclTQVXNKGC5komuedSsTLNsGQRZ3EMTHIQoJnmcSLYPNhMXtXBV9E70_o8RQem-Aedqwpwo5ENFmmuUxRlLnWmuCwBGNMsgkQkTPtrtHc9Tq7-ULaopI_ooLmQXk6sqYuqOxbcf50zwf4AK7iF-Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens</title><source>PubMed Central</source><creator>Ahmadzadeh, Ahmad ; Yekaninejad, Mir Saeed ; Jalili, Mohamad H ; Bahadoram, Mohammad ; Efazat, Mehdi ; Seghatoleslami, Mohammad ; Yazdi, Fatemeh ; Mahdipour, Mozhdeh ; Valizadeh, Armita ; Saki, Najmaldin</creator><creatorcontrib>Ahmadzadeh, Ahmad ; Yekaninejad, Mir Saeed ; Jalili, Mohamad H ; Bahadoram, Mohammad ; Efazat, Mehdi ; Seghatoleslami, Mohammad ; Yazdi, Fatemeh ; Mahdipour, Mozhdeh ; Valizadeh, Armita ; Saki, Najmaldin</creatorcontrib><description>In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with Hodgkin's lymphoma without any age restriction. After gathering all their data, we calculated their survival rate and the chance for a relapse and the secondary malignancies. 389 patients were included in the study with an average age of 27.5 years old and they had received only chemotherapy regimens. 87.9% of them had been treated by ABVD and 12.1 % by Stanford V regimen. 23.1% of them experienced a relapse and 13.1% of all patients, passed away during the study. Secondary malignancies were observed in 11 cases. An overall mean survival time of 295.31 months was resulted. The secondary malignancies after treating Hodgkin's lymphoma patients are different between chemotherapy regimens and chemotherapy – radiotherapy.</description><identifier>ISSN: 2008-3009</identifier><identifier>EISSN: 2008-2207</identifier><identifier>PMID: 24800035</identifier><language>eng</language><publisher>Tehran University of Medical Sciences</publisher><subject>Chemotherapy ; Hodgkin ; Original ; Second malignancy ; Survival</subject><ispartof>International journal of hematology- oncology and stem cell research, 2014, Vol.8 (2), p.21-26</ispartof><rights>2014 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003439/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003439/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,53791,53793</link.rule.ids></links><search><creatorcontrib>Ahmadzadeh, Ahmad</creatorcontrib><creatorcontrib>Yekaninejad, Mir Saeed</creatorcontrib><creatorcontrib>Jalili, Mohamad H</creatorcontrib><creatorcontrib>Bahadoram, Mohammad</creatorcontrib><creatorcontrib>Efazat, Mehdi</creatorcontrib><creatorcontrib>Seghatoleslami, Mohammad</creatorcontrib><creatorcontrib>Yazdi, Fatemeh</creatorcontrib><creatorcontrib>Mahdipour, Mozhdeh</creatorcontrib><creatorcontrib>Valizadeh, Armita</creatorcontrib><creatorcontrib>Saki, Najmaldin</creatorcontrib><title>Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens</title><title>International journal of hematology- oncology and stem cell research</title><description>In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with Hodgkin's lymphoma without any age restriction. After gathering all their data, we calculated their survival rate and the chance for a relapse and the secondary malignancies. 389 patients were included in the study with an average age of 27.5 years old and they had received only chemotherapy regimens. 87.9% of them had been treated by ABVD and 12.1 % by Stanford V regimen. 23.1% of them experienced a relapse and 13.1% of all patients, passed away during the study. Secondary malignancies were observed in 11 cases. An overall mean survival time of 295.31 months was resulted. The secondary malignancies after treating Hodgkin's lymphoma patients are different between chemotherapy regimens and chemotherapy – radiotherapy.</description><subject>Chemotherapy</subject><subject>Hodgkin</subject><subject>Original</subject><subject>Second malignancy</subject><subject>Survival</subject><issn>2008-3009</issn><issn>2008-2207</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkE1Lw0AQhoMoVmr_w948BTbZzcdeBCnVFipKrecw2Z1NVpNN2KSVHv3nLqaXnmZ4hnmYd66Cu5jSPIxjml2fe0apmAWLYTAl5TzjVKT0NpjFPKeUsuQu-F0doTnAaGxFxhrJx8EdjUdkByMSsGqiKDurwJ3IKzSmsmClwYGAHtGRvcNpf92p6tvYh4FsT21fdy2Qdz9BOw7kx4w1WdbYdt7noD-RHVamRTvcBzcamgEX5zoPPp9X--U63L69bJZP21DFPBvDkiPkEUIEOkmTSGclTQVXNKGC5komuedSsTLNsGQRZ3EMTHIQoJnmcSLYPNhMXtXBV9E70_o8RQem-Aedqwpwo5ENFmmuUxRlLnWmuCwBGNMsgkQkTPtrtHc9Tq7-ULaopI_ooLmQXk6sqYuqOxbcf50zwf4AK7iF-Q</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Ahmadzadeh, Ahmad</creator><creator>Yekaninejad, Mir Saeed</creator><creator>Jalili, Mohamad H</creator><creator>Bahadoram, Mohammad</creator><creator>Efazat, Mehdi</creator><creator>Seghatoleslami, Mohammad</creator><creator>Yazdi, Fatemeh</creator><creator>Mahdipour, Mozhdeh</creator><creator>Valizadeh, Armita</creator><creator>Saki, Najmaldin</creator><general>Tehran University of Medical Sciences</general><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2014</creationdate><title>Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens</title><author>Ahmadzadeh, Ahmad ; Yekaninejad, Mir Saeed ; Jalili, Mohamad H ; Bahadoram, Mohammad ; Efazat, Mehdi ; Seghatoleslami, Mohammad ; Yazdi, Fatemeh ; Mahdipour, Mozhdeh ; Valizadeh, Armita ; Saki, Najmaldin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d247t-b4ea81ea1af5651f7b0694d050908dc58af5cd3b67eb314322a3c4a9af3f42593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Chemotherapy</topic><topic>Hodgkin</topic><topic>Original</topic><topic>Second malignancy</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmadzadeh, Ahmad</creatorcontrib><creatorcontrib>Yekaninejad, Mir Saeed</creatorcontrib><creatorcontrib>Jalili, Mohamad H</creatorcontrib><creatorcontrib>Bahadoram, Mohammad</creatorcontrib><creatorcontrib>Efazat, Mehdi</creatorcontrib><creatorcontrib>Seghatoleslami, Mohammad</creatorcontrib><creatorcontrib>Yazdi, Fatemeh</creatorcontrib><creatorcontrib>Mahdipour, Mozhdeh</creatorcontrib><creatorcontrib>Valizadeh, Armita</creatorcontrib><creatorcontrib>Saki, Najmaldin</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of hematology- oncology and stem cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmadzadeh, Ahmad</au><au>Yekaninejad, Mir Saeed</au><au>Jalili, Mohamad H</au><au>Bahadoram, Mohammad</au><au>Efazat, Mehdi</au><au>Seghatoleslami, Mohammad</au><au>Yazdi, Fatemeh</au><au>Mahdipour, Mozhdeh</au><au>Valizadeh, Armita</au><au>Saki, Najmaldin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens</atitle><jtitle>International journal of hematology- oncology and stem cell research</jtitle><date>2014</date><risdate>2014</risdate><volume>8</volume><issue>2</issue><spage>21</spage><epage>26</epage><pages>21-26</pages><issn>2008-3009</issn><eissn>2008-2207</eissn><abstract>In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with Hodgkin's lymphoma without any age restriction. After gathering all their data, we calculated their survival rate and the chance for a relapse and the secondary malignancies. 389 patients were included in the study with an average age of 27.5 years old and they had received only chemotherapy regimens. 87.9% of them had been treated by ABVD and 12.1 % by Stanford V regimen. 23.1% of them experienced a relapse and 13.1% of all patients, passed away during the study. Secondary malignancies were observed in 11 cases. An overall mean survival time of 295.31 months was resulted. The secondary malignancies after treating Hodgkin's lymphoma patients are different between chemotherapy regimens and chemotherapy – radiotherapy.</abstract><pub>Tehran University of Medical Sciences</pub><pmid>24800035</pmid><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2008-3009
ispartof International journal of hematology- oncology and stem cell research, 2014, Vol.8 (2), p.21-26
issn 2008-3009
2008-2207
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_68f6e9b8cf7d4cbaa33f31a5953fd24f
source PubMed Central
subjects Chemotherapy
Hodgkin
Original
Second malignancy
Survival
title Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A14%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluating%20the%20Survival%20Rate%20and%20the%20Secondary%20Malignancies%20after%20Treating%20Hodgkin's%20Lymphoma%20Patients%20with%20Chemotherapy%20Regimens&rft.jtitle=International%20journal%20of%20hematology-%20oncology%20and%20stem%20cell%20research&rft.au=Ahmadzadeh,%20Ahmad&rft.date=2014&rft.volume=8&rft.issue=2&rft.spage=21&rft.epage=26&rft.pages=21-26&rft.issn=2008-3009&rft.eissn=2008-2207&rft_id=info:doi/&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_4003439%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d247t-b4ea81ea1af5651f7b0694d050908dc58af5cd3b67eb314322a3c4a9af3f42593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24800035&rfr_iscdi=true